Loading...
*  Differential modulation of excitatory and inhibitory striatal synaptic transmission by histamine. - Department of Pharmacology
... dopamine). The striatum also receives modulatory afferents from the histaminergic neurons in the hypothalamus which exhibit a ... Excitatory Amino Acid Agents, Excitatory Postsynaptic Potentials, Feedback, Physiological, Female, GABA Agents, Green ... Dopamine D1, Receptors, Dopamine D2, Rhodopsin, Synaptic Transmission, Thalamus, Transfection, Tyrosine 3-Monooxygenase, ... dopamine). The striatum also receives modulatory afferents from the histaminergic neurons in the hypothalamus which exhibit a ...
  https://pharm.ox.ac.uk/publications/329205
*  Effects of the single and combined treatment with dopamine agonist, somatostatin analog and mTOR inhibitors in a human lung...
Octreotide and cabergoline did not reduce cell viability as single agents but, when combined with mTOR inhibitors, they ... No data are available on dopamine agonists as treatment for lung carcinoids. The main aim of the current study was to evaluate ... Somatostatin receptor 2, dopamine receptor 2, and p70S6K (non phosphorylated and phosphorylated) proteins were expressed in ... Fifteen typical lung carcinoids tissue samples have been used for somatostatin receptor 2, dopamine receptor 2, and the main ...
  https://www.semanticscholar.org/paper/Effects-of-the-single-and-combined-treatment-with-Pivonello-Rousaki/af4bbd2208d6ecbadf96414caadefa1b747da8de
*  Influence of Age and Strain on Striatal Dopamine Loss in a Genetic Mouse Model of Lesch-Nyhan Disease - Jinnah - 1999 - Journal...
Advertisers & Agents Powered by Wiley Online Library. Copyright © 1999 - 2017 John Wiley & Sons, Inc. All Rights Reserved ... The magnitude of dopamine loss measurable is dependent on the genetic background of the mouse strain used, the basal ganglia ... Influence of Age and Strain on Striatal Dopamine Loss in a Genetic Mouse Model of Lesch-Nyhan Disease. Authors. *. H. A. Jinnah ... Caudoputamen dopamine concentrations were significantly reduced in all five of the strains, with deficits ranging from 50.7 to ...
  http://onlinelibrary.wiley.com/doi/10.1046/j.1471-4159.1999.0720225.x/abstract
*  Dopamine Agonists | Parkinson's Disease Clinic and Research Center
Treatment with dopamine agonists should begin at a low dose, which is increased at intervals (depending on the agent) until ... Prescribing dopamine agonists. The response to a particular dopamine agonist is idiosyncratic. If one dopamine agonists does ... Dopamine Agonists. Dopamine agonists differ from levodopa, since they do not have to be modified by brain enzymes in order to ... Although treatment with dopamine agonists causes motor fluctuations less frequently than levodopa, dopamine agonists are more ...
  http://pdcenter.neurology.ucsf.edu/professionals-guide/medications/dopamine-agonists
*  Dopaminergic - Wikipedia
Dopamine releasing agents (DRAs) such as phenethylamine, amphetamine, lisdexamfetamine (Vyvanse), methamphetamine, ... Dopaminergic means "related to dopamine" (literally, "working on dopamine"), dopamine being a common neurotransmitter. ... The excess dopamine resulting from inhibition of the dopamine β-hydroxylase enzyme increases unpleasant symptoms such as ... Dopamine reuptake inhibitors (DRIs) or dopamine transporter (DAT) inhibitors such as methylphenidate (Ritalin), bupropion ( ...
  https://en.wikipedia.org/wiki/Dopaminergic
*  Dopamine receptor D4 - Wikipedia
... a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction". Journal of Medicinal ... As with other dopamine receptor subtypes, the D4 receptor is activated by the neurotransmitter dopamine. It is linked to many ... The dopamine receptor D4 is a G protein-coupled receptor encoded by the DRD4 gene on chromosome 11 at 11p15.5. The structure of ... Wu J, Xiao H, Sun H, Zou L, Zhu LQ (June 2012). "Role of dopamine receptors in ADHD: a systematic meta-analysis". Molecular ...
  https://en.wikipedia.org/wiki/Dopamine_receptor_D4
*  List of MeSH codes (D16) - Wikipedia
... dopamine agents MeSH D27.505.519.625.150.151 --- dopamine agonists MeSH D27.505.519.625.150.175 --- dopamine antagonists MeSH ... dopamine agents MeSH D27.505.696.577.150.151 --- dopamine agonists MeSH D27.505.696.577.150.175 --- dopamine antagonists MeSH ... anti-allergic agents MeSH D27.505.954.122 --- anti-infective agents MeSH D27.505.954.122.085 --- anti-bacterial agents MeSH ... antiviral agents MeSH D27.505.954.122.388.077 --- anti-retroviral agents MeSH D27.505.954.122.388.077.088 --- anti-hiv agents ...
  https://en.wikipedia.org/wiki/List_of_MeSH_codes_(D16)
*  Spasmodic torticollis - Wikipedia
In the past, dopamine blocking agents have been used in the treatment of spasmodic torticollis. Treatment was based on the ... It has also been suggested that the functional imbalance is due to an imbalance of neurotransmitters such as dopamine, ... Relief from spasmodic torticollis is higher in those patients who take anticholinergic agents when compared to other oral ... of patients who use anticholinergic agents report relief, 21% of patients report relief from clonazepam, 11% of patients report ...
  https://en.wikipedia.org/wiki/Spasmodic_torticollis
*  Phenylpropanolamine - Wikipedia
PPA acts primarily as a selective norepinephrine releasing agent. It also acts as a dopamine releasing agent with around 10- ... Dopamine-β-hydroxylase catalyzed the removal of the pro-R hydrogen atom and the production of 1-norephedrine, (2S,1R)-2-amino-1 ... Agents such as metaraminol exhibit a greater degree of indirect sympathomimetic activity. Substitution on the β-Carbon Atom ... The metabolism of p-OHA to p-OHNor is well documented and dopamine-β hydroxylase present in noradrenergic neurons could easily ...
  https://en.wikipedia.org/wiki/Phenylpropanolamine
*  Clofenciclan - Wikipedia
Clofenciclan (Chlorphencyclan; Tonquil, Vesitan) is a dopamine-releasing agent developed by Boehringer & Soehne in the 1950s. ...
  https://en.wikipedia.org/wiki/Clofenciclan
*  Phendimetrazine - Wikipedia
Phenmetrazine (and therefore phendimetrazine as well) acts as a norepinephrine-dopamine releasing agent (NDRA). Its structure ...
  https://en.wikipedia.org/wiki/Phendimetrazine
*  Torsion dystonia - Wikipedia
... dopaminergic agents/dopamine-depleting agents, and tetrabenazine. Each medication is started on a low dosage and gradually ...
  https://en.wikipedia.org/wiki/Torsion_dystonia
*  3,4-Methylenedioxyamphetamine - Wikipedia
Relative to MDMA, MDA is also a more potent releasing agent of norepinephrine and dopamine and hence is more stimulating in ... In terms of pharmacology, MDA acts most importantly as a serotonin-norepinephrine-dopamine releasing agent (SNDRA). Due to its ... and for these reasons acts as a reuptake inhibitor and releasing agent of serotonin, norepinephrine, and dopamine (that is, it ... release of dopamine and norepinephrine is responsible for its psychostimulant effects, dopamine release is necessary for its ...
  https://en.wikipedia.org/wiki/3,4-Methylenedioxyamphetamine
*  Trifluoromethylphenylpiperazine - Wikipedia
More commonly, TFMPP is co-administered with BZP, which acts as a norepinephrine and dopamine releasing agent. Due to the ... It has no effects on dopamine or norepinephrine reuptake or efflux. TFMPP is rarely used by itself. In fact, TFMPP reduces ... serotonin agonist effects and increase in serotonin, norepinephrine, and dopamine levels produced by the BZP/TFMPP combination ...
  https://en.wikipedia.org/wiki/Trifluoromethylphenylpiperazine
*  3-Fluorophenmetrazine - Wikipedia
3-FPM acts as a norepinephrine-dopamine releasing agent with EC50 values of 43 nM and 30 nM, respectively. It shows only ...
  https://en.wikipedia.org/wiki/3-Fluorophenmetrazine
*  Serotonin-dopamine reuptake inhibitor - Wikipedia
A closely related type of drug is a serotonin-dopamine releasing agent (SDRA). Relative to serotonin-norepinephrine-dopamine ... and inhibit the reuptake of dopamine alone. As a result, selective dopamine reuptake inhibitors (DRIs) are rare, and comparably ... A serotonin-dopamine reuptake inhibitor (SDRI) is a type of drug which acts as a reuptake inhibitor of the monoamine ... Based on its chemical structure, UWA-101 may actually also possess some activity as a releasing agent, and if so, unlike RTI-83 ...
  https://en.wikipedia.org/wiki/Serotonin%E2%80%93dopamine_reuptake_inhibitor
*  Dimethoxymethamphetamine - Wikipedia
It appears to act as a serotonin-norepinephrine-dopamine releasing agent (SNDRA), although it is significantly less potent than ...
  https://en.wikipedia.org/wiki/Dimethoxymethamphetamine
*  Serotonin releasing agent - Wikipedia
They act as serotonin-norepinephrine-dopamine releasing agents (SNDRAs) and also agonize serotonin receptors such as those in ... A serotonin releasing agent (SRA) is a type of drug that induces the release of serotonin into the neuronal synaptic cleft. A ... Scorza C, Silveira R, Nichols DE, Reyes-Parada M (July 1999). "Effects of 5-HT-releasing agents on the extracellullar ... Scorza C, Silveira R, Nichols DE, Reyes-Parada M (July 1999). "Effects of 5-HT-releasing agents on the extracellullar ...
  https://en.wikipedia.org/wiki/Serotonin_releasing_agent
*  Ortho-Methylphenylpiperazine - Wikipedia
It acts as a serotonin-norepinephrine-dopamine releasing agent (SNDRA), with EC50 values for induction of monoamine release of ... The 2,3-methyl and 4-methyl analogues show diminished activity as dopamine releasing agents with respective EC50 values of ... and chemical perspectives on atypical agents targeting the dopamine transporter". Drug Alcohol Depend. 147: 1-19. doi:10.1016/j ... to 13.9-fold preference for induction of norepinephrine release over dopamine. ...
  https://en.wikipedia.org/wiki/Ortho-Methylphenylpiperazine
*  Modafinil - Wikipedia
In addition, modafinil fails to reverse reserpine-induced akinesia, whereas dextroamphetamine, a dopamine releasing agent (DRA ... Of the sites tested, it was found to significantly affect only the dopamine transporter (DAT), acting as a dopamine reuptake ... and chemical perspectives on atypical agents targeting the dopamine transporter". Drug and Alcohol Dependence. 147: 1-19. doi: ... "Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications". Jama. 301 (11): ...
  https://en.wikipedia.org/wiki/Modafinil
*  Monoamine releasing agent - Wikipedia
Serotonin-dopamine releasing agent (SDRA) Serotonin-norepinephrine-dopamine releasing agent (SNDRA) MRAs cause the release of ... Dopamine releasing agent (DRA) Non-selective, releasing two or more neurotransmitters Norepinephrine-dopamine releasing agent ( ... Dopamine release agents, usually selective for both norepinephrine and dopamine have psychostimulant effect, causing an ... Less selective serotonergic agents that stimulate an efflux in dopamine, such as MDMA are described as more pleasant, ...
  https://en.wikipedia.org/wiki/Monoamine_releasing_agent
*  Dopamine antagonist - Wikipedia
MeSH list of agents 82018492 Dopamine antagonists at the US National Library of Medicine Medical Subject Headings (MeSH). ... A dopamine antagonist (antidopaminergic) is a type of drug which blocks dopamine receptors by receptor antagonism. Most ... Several other dopamine antagonists are antiemetics used in the treatment of nausea and vomiting. Dopamine receptor antagonists ... trimipramine Choline can antagonize dopamine directly or interfere with receptor function Melatonin suppresses dopamine ...
  https://en.wikipedia.org/wiki/Dopamine_antagonist
*  Tranylcypromine - Wikipedia
Compared to amphetamine, tranylcypromine shows low potency as a dopamine releasing agent, with even weaker potency for ... This leads to an increase in the availability of monoamines, such as serotonin, norepinephrine, and dopamine, as well as a ... It is used as an antidepressant and anxiolytic agent in the clinical treatment of mood and anxiety disorders, respectively. ... alternative agents are recommended. Other studies have come to similar conclusions. Pharmacokinetic interactions with ...
  https://en.wikipedia.org/wiki/Tranylcypromine
*  Iodobenzamide - Wikipedia
... a potential CNS D-2 dopamine receptor imaging agent". Nuclear Medicine and Biology. 15 (2): 195-201. doi:10.1016/0883-2897(88) ... Pharmaceutically it is a dopamine antagonist and it can be used by nuclear medicine physicians as a radioactive tracer for ... Kung, Hank, F.; Alavi; Chang; Kung; Keyes; Velchik; Billings; Pan; Noto (1990). "In vivo SPECT imaging of CNS D-2 dopamine ...
  https://en.wikipedia.org/wiki/Iodobenzamide
*  Pleurothotonus - Wikipedia
Acute dystonia nearly always develops a few weeks after a dopamine blocking agent/medication has begun or a substantial ... Tardive dykinesias have also been associated with polymorphism in the dopamine receptor D2 gene, dopamine receptor D3 gene, ... The human dopamine receptor D2 (DRD2) gene is associated with tardive dyskinesia in patients with schizophrenia. Schizophr Res ... Acute effects of dopamine antagonists also include Parkinsons-like symptoms, manifested by bradykinesia, pin rolling tremor, ...
  https://en.wikipedia.org/wiki/Pleurothotonus